Skip to main navigation Skip to search Skip to main content

CRISPR in Thalassemia: Global Research Trend Analysis

  • Muhammad Saboor
  • , Maryam Jasem Alblooshi
  • , Alreem Adel Alkaabi
  • , Fatemeh Ramazan Soozaei
  • , Moza Hamad Alketbi
  • University of Sharjah

Research output: Contribution to journalArticlepeer-review

Abstract

β-Thalassemia is a prevalent inherited disorder of β-globin chains. The clustered regularly interspaced short palindromic repeats (CRISPR) genome editing system has emerged as a potential curative strategy. We conducted a bibliometric analysis to map global research trends in CRISPR-based thalassemia research. Original and review research articles were retrieved from the Scopus database using the search terms [TITLE-ABS-KEY (‘βeta thalassemia’ OR ‘β thalassemia’ OR thalassemia*) AND TITLE-ABS-KEY (‘gene edit*’ OR crispr* OR ‘clustered regularly interspaced short palindromic repeats’)] AND [LIMIT-TO (DOCTYPE, ‘re’) OR LIMIT-TO (DOCTYPE, ‘ar’)] for analysis. Bibliometric mapping and network visualization were performed using VOSviewer to analyze publication trends, authorship networks, international collaborations, keyword clusters, and citation metrics. Major CRISPR-based therapeutic strategies for thalassemia were reviewed to place experimental and clinical developments within a translational framework. The analysis demonstrates a clear transition from foundational genomic studies to translational applications, with leading contributions from the United States and China. Two dominant therapeutic strategies have emerged: direct correction of the HBB gene in hematopoietic stem cells and fetal hemoglobin reactivation via BCL11A repression. The latter strategy culminated in regulatory approval of exagamglogene autotemcel (Casgevy). Advances in base editing, prime editing, and strategies to improve engraftment are expected to enhance the precision and long-term efficacy of next-generation approaches. Clustered regularly interspaced short palindromic repeats-based research on thalassemia continues to expand, supported by extensive international collaboration and growing clinical translation. Future large-scale implementation will require advances in bioprocess engineering, cost reduction for ex vivo manufacturing, and adaptable treatment models for diverse healthcare systems.

Original languageEnglish
Pages (from-to)141-155
Number of pages15
JournalHemoglobin
Volume50
Issue number2
DOIs
StatePublished - 2026

Keywords

  • CRISPR
  • Thalassemia
  • bibliographic analysis
  • gene editing
  • hemoglobin

Fingerprint

Dive into the research topics of 'CRISPR in Thalassemia: Global Research Trend Analysis'. Together they form a unique fingerprint.

Cite this